glp-1 and dpp-4 inhibitors GLP-1RAs: cardiovascular safety and benefits Frontiers | DPP-4 Inhibitors as
Description
In clinical studies of GLP-1RA plus SGLT2i combination therapy, the safety profile of the combination therapy was consistent with those of the individual agents, with no unexpected findings [9]
392:2089-2099 [PubMed: 40305708] 339
Theres never any pressure just facts and, when needed, sound consultation
[DOI] [PMC free article] [PubMed] [Google Scholar] 94.Joo JH, Sharma N, Shaia J, Wu AK, Skugor M, Singh RP, et al
If one provider recommends modifying your GLP-1 therapy due to eye concerns, make sure the other knows
